Henrik Einwächter1. 1. Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, München, Germany.
Abstract
BACKGROUND: The incidence of Crohn's disease (CD) is rising, and still many patients have to undergo repeated surgery due to failure of pharmacologic therapy. RESULTS: While the introduction of anti-TNF agents started biologic therapy for CD and revolutionized the management of patients, the number of patients who do not respond to this treatment or lose their initial response to this treatment is still substantial. Therefore, the recent introduction of new therapeutic options with anti-integrins and new anti-cytokines was an important step to provide more effective treatment for our patients. Yet, next to new drugs also new treatment strategies have been proposed. CONCLUSION: In this article, we will review these new aspects of pharmacologic therapy for CD -patients.
BACKGROUND: The incidence of Crohn's disease (CD) is rising, and still many patients have to undergo repeated surgery due to failure of pharmacologic therapy. RESULTS: While the introduction of anti-TNF agents started biologic therapy for CD and revolutionized the management of patients, the number of patients who do not respond to this treatment or lose their initial response to this treatment is still substantial. Therefore, the recent introduction of new therapeutic options with anti-integrins and new anti-cytokines was an important step to provide more effective treatment for our patients. Yet, next to new drugs also new treatment strategies have been proposed. CONCLUSION: In this article, we will review these new aspects of pharmacologic therapy for CD -patients.
Authors: Sam Khorrami; Daniel Ginard; Ignacio Marín-Jiménez; María Chaparro; Mónica Sierra; Mariam Aguas; Beatriz Sicilia; Valle García-Sánchez; Cristina Suarez; Albert Villoria; Carlos Taxonera; Antonio Velasco-Guardado; Javier Martínez-González; Javier P Gisbert Journal: Inflamm Bowel Dis Date: 2016-07 Impact factor: 5.325
Authors: C Ma; R N Fedorak; G G Kaplan; L A Dieleman; S M Devlin; N Stern; K I Kroeker; C H Seow; Y Leung; K L Novak; B P Halloran; V W Huang; K Wong; P K Blustein; S Ghosh; R Panaccione Journal: Aliment Pharmacol Ther Date: 2017-03-02 Impact factor: 8.171
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts Journal: N Engl J Med Date: 2016-11-17 Impact factor: 91.245
Authors: Jean-Frédéric Colombel; Bruce E Sands; Paul Rutgeerts; William Sandborn; Silvio Danese; Geert D'Haens; Remo Panaccione; Edward V Loftus; Serap Sankoh; Irving Fox; Asit Parikh; Catherine Milch; Brihad Abhyankar; Brian G Feagan Journal: Gut Date: 2016-02-18 Impact factor: 23.059